Let's hope that the parallel dose does get the go ahead but we should not forget that having approval and having two patients ready to go at the same time are not one and the same. The other point here is that if two patient are just about ready to go using only the existing two clinical sites, then why did we bother trying (so far unsuccessfully) to bring on-board five more clinical sites?
Sanofi Signs Benitec's closest competitor Voyager for $845M, page-27
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)